Earn CME for related activities: [ Ссылка ]
In this webcast from the 'Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges' symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Gail J. Roboz discusses the use of MRD as a target for the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
Measurable Residual Disease (MRD) in AML and ALL
Теги
ImedexCMEContinuing Medical EducationEducationAccreditationMedicalNurseResidents-in-TrainingFellowsPhysicianClinicianPhysician-in-trainingHMP CMEblood cancerhematologic malignancyhematologic malignancieshematologic oncologyoncologyongologistAMLALLacute leukemiaacute myeloid leukemiaacute lymphocytic leukemiaminimal residual diseasemeasurable residual diseaseMRDMRD testing
